The U.S. Food and Drug Administration approved the abbreviated new drug application of Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Changzhou Pharmaceutical Factory, for doxycycline capsules, according to a Shanghai bourse filing on Wednesday.
The drug is used to treat adult patients with inflammatory lesions of rosacea.